IP Library Patent Application 13137101
Patent Application
App. No. 13/137,101

Method for prongf assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of prongf

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/137,101
Abstract

A ProNGF inhibitor for preparing a drug, said drug being in particular useful for blocking remote dissemination and cell invasion in patients suffering from cancer, in particular breast, thyroid or lung cancer.

Claims (10)

1 . A method for treatment of a patient suffering from cancer, comprising administering a therapeutically effective amount of a ProNGF inhibitor to said patient.

2 . The method as claimed in claim 1 , wherein the amount is effective for blocking cell migration or invasion in patients suffering from cancer.

3 . The method as claimed in claim 1 , wherein the ProNGF inhibitor is an anti-ProNGF antibody or a ProNGF receptor analog in soluble form.

4 . The method as claimed in claim 1 , wherein said ProNGF inhibitor is able to specifically penetrate into cells of interest.

5 . The method as claimed in claim 1 , wherein the ProNGF inhibitor is an siRNA of a ProNGF receptor.

6 . A method of blocking cancerous cell migration, comprising administering an effective amount of a ProNGF inhibitor to a person, thereby blocking migration of cancer cells.

7 . A pharmaceutical composition, comprising, as an active ingredient, at least one ProNGF inhibitor in combination with a pharmaceutually acceptable excipient.

8 . A pharmaceutical composition as claimed in claim 7 , wherein the ProNGF inhibitor is an anti-ProNGF antibody or a ProNGF receptor analog in soluable form.

9 . A pharmaceutical composition as claimed in claim 7 , wherein the ProNGF inhibitor is an siRNA of a ProNGF receptor.

10 . A pharmaceutical composition as claimed in claim 7 , wherein said ProNGF inhibitor is able to specifically penetrate into cells of interest.